Since 2017, four new cell and gene therapies have become available in the U.S. with prices ranging from $373,000 to $2.1 million for a one-time administration.
This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents.
